Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome.
about
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.Biological Modulators in Eosinophilic Diseases.Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.Imatinib for the treatment of hypereosinophilic syndromes.Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome.Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
P2860
Q33718814-24F1C5EE-5F0D-4E59-9294-E9BB2F0667EEQ37362888-DCF6D0FF-4969-42D5-B9B5-6C03D20F2524Q38191834-44DF5368-AD7B-4FA8-8E89-218B8E25676AQ38240474-8AFFBC89-3236-4A7C-BB5D-5D73F26872B7Q40115606-22E6F924-B88F-4BC8-81C2-B8E337787D9FQ43175119-35E63F81-3204-4E9E-B2D9-23F0D14E4B24Q43470981-E96C94C7-0FF6-433D-8428-2CBBE4097F7DQ44652111-16BC9C47-EE83-4C59-B121-05ECC28A78E9Q46026437-74BBD046-1A7B-46BE-8527-38AE1B1AEB2EQ50177622-06F45FBB-B219-4192-9A34-9B1A9B9EC30DQ50996871-8CB45695-6D81-4C08-B18E-A2E133433A62Q52912578-895C5003-967B-40F6-A351-F966EB5E486C
P2860
Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Long-term follow-up of FIP1L1- ...... survival and clinical outcome.
@en
Long-term follow-up of FIP1L1- ...... survival and clinical outcome.
@nl
type
label
Long-term follow-up of FIP1L1- ...... survival and clinical outcome.
@en
Long-term follow-up of FIP1L1- ...... survival and clinical outcome.
@nl
prefLabel
Long-term follow-up of FIP1L1- ...... survival and clinical outcome.
@en
Long-term follow-up of FIP1L1- ...... survival and clinical outcome.
@nl
P2093
P356
P1433
P1476
Long-term follow-up of FIP1L1- ...... survival and clinical outcome.
@en
P2093
A Pardanani
C A Hanson
R A Knudson
P2888
P304
P356
10.1038/LEU.2012.162
P577
2012-06-18T00:00:00Z